GlassScriptPhysician profile
Casey N Long
NPI 1548939796
$2,037.72
in general payments reported to CMS, 2019-2025
17 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.85 · 2022: $284 · 2023: $368 · 2024: $848 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $251.16 | 2023-2024 | |
| Gilead Sciences, INC. | $211.70 | 2022-2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $138.03 | 2024 | Austedo Xr |
| Eisai INC. | $123.81 | 2025 | |
| Idorsia Pharmaceuticals US INC | $123.52 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $122.90 | 2024 | Ultomiris |
| Lilly USA, LLC | $122.38 | 2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $119.70 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $115.89 | 2025 | Auvelity |
| Madrigal Pharmaceuticals | $114.32 | 2025 | Rezdiffra |
| Abiomed | $114.12 | 2024 | Impella |
| Neurelis, INC. | $111.57 | 2024 | Valtoco |
| Esperion Therapeutics, INC. | $95.85 | 2021 | |
| Shionogi INC | $92.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $87.33 | 2025 | Breztri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.47 | 2022 | |
| Masimo Corporation | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.